Oryn Therapeutics is pioneering a new class of therapeutics known as Orynotides, which are bioinspired by theta-defensins, naturally occurring peptides found in non-human primates. These novel compounds are designed to address complex and difficult-to-treat diseases, including autoimmune disorders, chronic inflammatory diseases, and various infections. Orynotides are characterized by their safety, stability, low toxicity, and low immunogenicity, making them easier to produce and suitable for a broad range of therapeutic applications. The company aims to improve the quality of life for patients by developing treatments that are not only effective but also carry reduced risks compared to existing therapies.

The therapeutic potential of Orynotides has been validated through successful preclinical studies and the completion of a Phase 1B trial for rheumatoid arthritis, demonstrating their safety and tolerability. Oryn Therapeutics is focused on expanding the applications of Orynotides to include treatments for COVID-19, inflammatory bowel disease, and cancer, among others. By leveraging the unique properties of these cyclic peptides, Oryn Therapeutics is positioned to lead in the development of innovative therapies that can effectively manage autoimmune diseases, chronic inflammation, and infectious diseases, while also exploring combination immunotherapy strategies for cancer treatment.

United States

Oryn Therapeutics is a clinical-stage company developing a new class of drug candidates, Orynotides. These proprietary drug candidates are engineered, stable, cyclic peptides with very low immunogenicity and toxicity. They modulate pathologic inflammation and have proven effective in animal models of autoimmune and chronic inflammatory diseases such as rheumatoid arthritis and ulcerative colitis. They have proven effective in preclinical cancer models and augment natural host defense, functioning as host-directed anti-infectives against drug resistant pathogens.

Oryn Therapeutics

Company Details